Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus BENADRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus BENADRYL.
ACTIDIL vs BENADRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Category C
Category C
Antihistamine
Antihistamine